Overview
Compare with Astrotech Corporation, SCIENTIFIC INDUSTRIES INC or Lifeloc Technologies, Inc, or pick any stock.
- TickerBFNH on OTC1
- IndustryLaboratory Analytical Instruments1
- HeadquartersVirginia Beach, Virginia1
- Business address2020 General Booth Blvd, Suite 230, Virginia Beach, Va 234542
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
100 common shares (see Exhibit 3.2). As of the date of this filing, there are no Series 'A' Preferred shares issued or outstanding.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2019
Where the money goes
Where each dollar of revenue went, fiscal 2019
- Cost of revenue75¢$13.4K
- Other costs25¢$4.4K
Out of $17.8K in revenue.45 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Board of Directors Compensation | $423.0K | $423.0K |
| General and Administrative | $67.0K | $67.4K |
| Total Expenses | $490.0K | $490.4K |
| Loss from Operations Before Loss on Liability Settlement | -$490.0K | -$490.4K |
| Loss on Liability Settlement | -$802.0K | |
| Net Loss | -$1.3M | -$490.4K |
| Weighted Average Number of Common Shares - Basic | 33.2M shares | 29.3M shares |
| Weighted Average Number of Common Shares - Diluted | 33.2M shares | 29.3M shares |
| Net Loss for the Period Per Common Shares - Basic | -$0.04 | -$0.02 |
| Net Loss for the Period Per Common Shares - Diluted | -$0.04 | -$0.02 |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.9
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $786 | $862 | |
| Total Current Assets | $786 | $862 | |
| Total Assets | $786 | $862 | |
| Accounts Payable and Accrued Expenses | $11.8K | $8.8K | |
| Accrued Board of Directors Compensation | $506.2K | $2.0M | |
| Due to Related Parties | $101.3K | $274.1K | |
| Total Current Liabilities | $619.3K | $2.3M | |
| Total Liabilities | $619.3K | $2.3M | |
| Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 33,521,755 and 29,271,755 Issued and Outstanding, Respectively | $33.5K | $29.3K | |
| Additional Paid-In-Capital | $161.8M | $158.8M | |
| Accumulated Deficit | -$162.4M | -$161.1M | |
| Total Stockholders' Deficit | -$618.5K | -$2.3M | -$1.8M |
| Total Liabilities and Stockholders' Deficit | $786 | $862 | |
| Preferred stock, par value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, shares authorized | 900.0M shares | 900.0M shares | |
| Common stock, shares issued | 33.5M shares | 29.3M shares | |
| Common stock, shares outstanding | 33.5M shares | 29.3M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $786 | $862 | |
| Total Current Assets | $786 | $862 | |
| Total Assets | $786 | $862 | |
| Accounts Payable and Accrued Expenses | $11.8K | $8.8K | |
| Accrued Board of Directors Compensation | $506.2K | $2.0M | |
| Due to Related Parties | $101.3K | $274.1K | |
| Total Current Liabilities | $619.3K | $2.3M | |
| Total Liabilities | $619.3K | $2.3M | |
| Common Stock - $0.001 Par; 900,000,000 Shares Authorized, 33,521,755 and 29,271,755 Issued and Outstanding, Respectively | $33.5K | $29.3K | |
| Additional Paid-In-Capital | $161.8M | $158.8M | |
| Accumulated Deficit | -$162.4M | -$161.1M | |
| Total Stockholders' Deficit | -$618.5K | -$2.3M | -$1.8M |
| Total Liabilities and Stockholders' Deficit | $786 | $862 | |
| Preferred stock, par value per share | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 100.0M shares | 100.0M shares | |
| Common stock, par value per share | $0.00 | $0.00 | |
| Common stock, shares authorized | 900.0M shares | 900.0M shares | |
| Common stock, shares issued | 33.5M shares | 29.3M shares | |
| Common stock, shares outstanding | 33.5M shares | 29.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.9
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$1.3M | -$490.4K |
| Loss on Liability Settlement | $802.0K | |
| Accounts Payable and Accrued Expenses | $3.0K | $6.2K |
| Accrued Board of Directors Compensation | $421.8K | $423.0K |
| Net Cash Flows Used In Operating Activities | -$65.2K | -$61.2K |
| Capital Contributions | $8.1K | |
| Proceeds from Related Parties | $65.1K | $53.4K |
| Net Cash Flows Provided by Financing Activities | $65.1K | $61.5K |
| Net Change in Cash | -$76 | $224 |
No quarter-by-quarter statement was filed.
Compare BIOFORCE NANOSCIENCES HOLDINGS, INC. with another company
Corporate structure
BIOFORCE NANOSCIENCES HOLDINGS, INC. sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of BIOFORCE NANOSCIENCES HOLDINGS, INC.
- Nexus Capital Investments, Inc. Filed SCHEDULE 13D on BIOFORCE NANOSCIENCES HOLDINGS, INC., latest Sep 4, 2026
- BIOFORCE NANOSCIENCES HOLDINGS, INC. Virginia Beach, Virginia
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What BIOFORCE NANOSCIENCES HOLDINGS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
Properties, in its own words
The Company makes use of the office space of Yes International, which is owned and operated by Richard Kaiser, a Director, CFO and the Secretary of the Company. As a result, the Company neither rents nor owns any properties. The Company currently has no policy with respect to investments or interests in real estate, real estate mortgages or securities of, or interests in, persons primarily engaged in real estate activities.
Item 2 of the 10-K filed Apr 15, 2026.3
Leadership
Who has led BIOFORCE NANOSCIENCES HOLDINGS, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
Chief operating officer
- Chief executive officerRichard Kaiser Kaiser Sep 2, 2026 to now10
- Chief executive officerMerle Ferguson Aug 10, 2018 to Oct 18, 202311
- Chief executive officerKerry M. Frey Jun 12, 2008 to Mar 17, 200912
- Chief executive officerEric Henderson Feb 5, 2007 to Jun 15, 200713
- PresidentMerle Ferguson Aug 10, 2018 to Apr 2, 202011
- PresidentEric Henderson Feb 5, 2007 to Jun 15, 200713
- PresidentKerry M. Frey Jun 15, 2007 to Mar 17, 200914
- Chief financial officerRichard Kaiser Kaiser Aug 10, 2018 to now15
- Chief operating officerKerry M. Frey Feb 5, 2007 to Jun 15, 200716
Board members and other officers (10)
- Exec VP and CSOEric Henderson Jun 12, 2008 to Mar 17, 200917
- Executive VP, CSO and DirectorKerry M. Frey Sep 23, 2008 to Sep 23, 200818
- Board memberScott Mager Sep 3, 2026 to now19
- Board memberMerle Ferguson Aug 10, 2018 to now11
- Board memberRichard Kaiser Kaiser Aug 10, 2018 to now15
- Board memberKerry M. Frey Feb 5, 2007 to Mar 17, 200916
- Board memberMichael D. Dunham Oct 3, 2007 to Nov 21, 200820
- Board memberEric Henderson Mar 13, 2006 to Mar 17, 200921
- Board memberJean-Jacques Sunier Mar 13, 2006 to Nov 21, 200822
- Board memberLawrence Gold Mar 13, 2006 to Nov 24, 200823
Former names
- SILVER RIVER VENTURES, INC.Dec 14, 2004 to Feb 24, 20062
Timeline
- Oct 7, 20268-K Other events24
- Sep 4, 20268-K Unregistered sale of shares25
- Sep 2, 2026New chief executive Richard Kaiser Kaiser becomes CEO10
- Aug 18, 20268-K Regulation FD disclosure26
- Aug 14, 20268-K Other events27
- Jul 7, 20268-K Other events28
- Jul 1, 20268-K Other events29
- Jun 18, 20268-K Change in control; Executive or director change; Other events30
- May 7, 20248-K Change of auditor31
- Nov 30, 20218-K Executive or director change32
- Aug 10, 2018New chief executive Merle Ferguson becomes CEO11
- Jun 12, 2008New chief executive Kerry M. Frey becomes CEO12
- Feb 5, 2007New chief executive Eric Henderson becomes CEO13
Filings
43 filings to the SEC since October 2021: 5 annual reports, 16 quarterly reports, 9 major events, 8 insider forms, 1 large holders, 4 other. The latest 20:
- Oct 7, 20268-K CURRENT REPORT EDGAR
- Sep 4, 2026SCHEDULE 13D EDGAR
- Sep 4, 20268-K CURRENT REPORT EDGAR
- Sep 4, 20263 PRIMARY DOCUMENT EDGAR
- Sep 3, 20263 PRIMARY DOCUMENT EDGAR
- Sep 2, 20264 PRIMARY DOCUMENT EDGAR
- Sep 2, 20264 PRIMARY DOCUMENT EDGAR
- Aug 18, 20268-K CURRENT REPORT EDGAR
- Aug 14, 20268-K CURRENT REPORT EDGAR
- Aug 10, 202610-Q QTR. REPORT - JUNE 30, 2026 EDGAR
- Jul 7, 20268-K CURRENT REPORT EDGAR
- Jul 1, 20268-K CURRENT REPOT EDGAR
- Jun 18, 20268-K CURRENT REPORT EDGAR
- May 19, 202610-Q QTR. REPORT - MARCH 31, 2026 EDGAR
- May 13, 2026NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Apr 15, 202610-K YEAR- END REPORT - DEC. 31, 2025 EDGAR
- Mar 31, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
- Nov 19, 202510-Q QTR. REPORT - SEPTEMBER 30, 2025 EDGAR
- Nov 13, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- Aug 11, 202510-Q QTR. REPORT - JUNE 30, 2025 EDGAR
The 43 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
1 open-market trades by officers, directors and large owners since October 2021: 0 buys and 1 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Apr 22, 2026 | Ferguson MerleDirector | Sale | 26,700,000 | $0.02 | $534.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Nexus Capital Investments, Inc.SCHEDULE 13D, 1 filing Sep 4, 202633
SEC filer profile
How BIOFORCE NANOSCIENCES HOLDINGS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBIOFORCE NANOSCIENCES HOLDINGS, INC.1
- CIK0001310488
- Employer ID (EIN)74-30781253
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inNevada3
- Fiscal year endsDecember 311
- Industry code (SIC)3826 Laboratory Analytical Instruments1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address2020 General Booth Blvd, Suite 230, Virginia Beach, VA 234541
- Phone757-306-60901
- Shares outstanding33,549,005 as of Aug 10, 20268
- Public float$2.6M as of Jun 30, 20253
- AuditorMICHAEL GILLESPIE & ASSOCIATES, PLLC, Vancouver, Washington PCAOB ID 61083
- On EDGAR sinceDec 14, 20041
- Filings253 in all: 4 (47), 8-K (44), 10-Q (28), 3 (15), UPLOAD (15), CORRESP (11), 10QSB (10), 10-K (9)1
All 37 form types
3/A (7), 10-12G/A (6), 4/A (6), NT 10-K (5), NT 10-Q (5), 10KSB (4), 10QSB/A (4), 8-K/A (4), SC 13D/A (4), 10-Q/A (3), 424B3 (2), DEF 14C (2), DEFR14C (2), EFFECT (2), POS AM (2), PRE 14C (2), SC 13D (2), 10-12G (1), 10-K/A (1), 10KSB/A (1), 10SB12G (1), 10SB12G/A (1), 15-12G (1), DEF 14A (1), PRER14C (1), REGDEX (1), SB-2 (1), SB-2/A (1), SCHEDULE 13D (1)
- Latest filingsAnnual report (10-K) Apr 15, 2026
Quarterly report (10-Q) Aug 10, 2026
Proxy statement (DEF 14A) Apr 14, 2008
Latest 8-K (8-K) Oct 7, 2026
Risk factors and legal proceedings
Legal proceedings
At this time, there are no material pending legal proceedings to which the Company is a party or as to which any of its property is subject, and no such proceedings are known to the Company to be threatened or contemplated against it.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARKerry M. Frey, President
- 15
- 16
- 17SEC EDGAREric Henderson, Exec VP and CSO
- 18
- 19SEC EDGARScott Mager, Board member
- 20SEC EDGARMichael D. Dunham, Board member
- 21SEC EDGAREric Henderson, Board member
- 22SEC EDGARJean-Jacques Sunier, Board member
- 23SEC EDGARLawrence Gold, Board member
- 24SEC EDGAROther events
- 25SEC EDGARUnregistered sale of shares
- 26SEC EDGARRegulation FD disclosure
- 27SEC EDGAROther events
- 28SEC EDGAROther events
- 29SEC EDGAROther events
- 30
- 31SEC EDGARChange of auditor
- 32SEC EDGARExecutive or director change
- 33